Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

• Status: Terminated
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Imatinib Mesylate; Mitogens

Criteria

Inclusion Criteria:

1. Histologically documented diagnosis of GBM.

2. Immunohistochemical documentation of expression of PDGFR.

3. Unresectable, recurrent disease by MRI and spectroscopy

Exclusion Criteria:

1. Treatment with any other investigational agents within 28 days of first day of study drug dosing.

2. Concurrent chemotherapy.

3. Concurrent radiotherapy.

Other protocol-defined exclusion criteria may apply.